In Taiwan, osimertinib EAP was approved by the Taiwan Food and Drug Administration for the treatment of EGFR T790M-positive locally advanced or metastatic NSCLC from October 2015 to September 2016. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.